tiprankstipranks
Blueprint Medicines (GB:0HOJ)
LSE:0HOJ

Blueprint Medicines Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
15Ratings
10 Buy
3 Hold
2 Sell
Based on 15 analysts giving stock ratings to
Blueprint
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HOJ Stock Price Prediction

Average Price Target

$89.93
▲(14.71% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $89.93 with a high forecast of $152.00 and a low forecast of $41.00. The average price target represents a 14.71% change from the last price of $78.40.
Highest Price Target$152.00Average Price Target$89.93Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
SVB Securities
$57.00
Hold
-27.29%
Downside
Assigned
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (NASDAQ: BLUE), Blueprint Medicines (NASDAQ: BPMC) and Gossamer Bio (NASDAQ: GOSS)
H.C. Wainwright
$80.00
Buy
2.05%
Upside
Reiterated
Blueprint Medicines (BPMC) Gets a Buy from H.C. Wainwright
Citigroup
$41.00
Sell
-47.70%
Downside
Reiterated
Blueprint Medicines faces high bar for success in PIONEER Part 2, says CitiBlueprint Medicines faces high bar for success in PIONEER Part 2, says Citi
Goldman Sachs
$143.00
Buy
82.41%
Upside
Reiterated
Raymond James
$115.00
Buy
46.69%
Upside
Reiterated
Raymond James Maintains Strong Buy on Blueprint Medicines, Lowers Price Target to $115
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0HOJ Stock Forecast FAQ

What is GB:0HOJ’s average 12-month price target, according to analysts?
Based on analyst ratings, Blueprint Medicines’s 12-month average price target is $89.93.
    What is GB:0HOJ’s upside potential, based on the analysts’ average price target?
    Blueprint Medicines has 14.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GB:0HOJ a Buy, Sell or Hold?
          Blueprint Medicines has a conensus rating of Moderate Buy which is based on 10 buy ratings, 3 hold ratings and 2 sell ratings.
            What is Blueprint Medicines’s price target?
            The average price target for Blueprint Medicines is $89.93. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $152.00 ,the lowest forecast is $41.00. The average price target represents 14.71% Increase from the current price of $78.395.
              What do analysts say about Blueprint Medicines?
              Blueprint Medicines’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis